BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dworakowska D, Grossman AB. Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer 2018;25:R559–R575. [PMID: 30306782 DOI: 10.1530/ERC-18-0228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Dai C, Kang J, Liu X, Yao Y, Wang H, Wang R. How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies. Front Endocrinol (Lausanne) 2021;12:604644. [PMID: 33815274 DOI: 10.3389/fendo.2021.604644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu J, He Y, Zhang X, Yan X, Huang Y. Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification. Oncol Lett 2020;19:1890-8. [PMID: 32194684 DOI: 10.3892/ol.2020.11263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mahboobifard F, Bidari-Zerehpoosh F, Davoudi Z, Panahi M, Dargahi L, Pourgholami MH, Sharifi G, Izadi N, Jorjani M. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics. Pituitary 2020;23:232-45. [PMID: 32026205 DOI: 10.1007/s11102-020-01029-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Flores-Martinez Á, Venegas-Moreno E, Dios E, Remón-Ruiz P, Gros-Herguido N, Vázquez-Borrego MC, Madrazo-Atutxa A, Japón MA, Kaen A, Cárdenas-Valdepeñas E, Roldán F, Castaño JP, Luque RM, Cano DA, Soto-Moreno A. Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. J Clin Med 2020;9:E3052. [PMID: 32971845 DOI: 10.3390/jcm9093052] [Reference Citation Analysis]
5 Burcea I, Poiana C. UPDATES IN AGGRESSIVE PITUITARY TUMORS. Acta Endocrinol (Buchar) 2020;16:267-73. [PMID: 33029249 DOI: 10.4183/aeb.2020.267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Postma MR, Kuijlen JMA, Korsten AGW, Westerlaan HE, van den Bergh ACM, Nuver J, den Dunnen WFA, van den Berg G. An aggressive poorly differentiated plurihormonal Pit-1-positive adenoma. Endocrinol Diabetes Metab Case Rep 2021;2021:EDM200166. [PMID: 34673544 DOI: 10.1530/EDM-20-0166] [Reference Citation Analysis]
7 Lamb LS, Sim HW, McCormack AI. Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?". Cancers (Basel) 2020;12:E308. [PMID: 32012988 DOI: 10.3390/cancers12020308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Yang Q, Li X. Molecular Network Basis of Invasive Pituitary Adenoma: A Review. Front Endocrinol (Lausanne) 2019;10:7. [PMID: 30733705 DOI: 10.3389/fendo.2019.00007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
9 Chen C, Hu Y, Lyu L, Yin S, Yu Y, Jiang S, Zhou P. Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004-2016. Sci Rep 2021;11:15155. [PMID: 34312470 DOI: 10.1038/s41598-021-94658-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Dekkers OM, Karavitaki N, Pereira AM. The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord 2020;21:209-12. [PMID: 32361816 DOI: 10.1007/s11154-020-09556-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lamb LS, Sim HW, McCormack AI. Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne) 2020;11:576027. [PMID: 33312158 DOI: 10.3389/fendo.2020.576027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Biagetti B, Simò R. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications. Int J Mol Sci 2021;22:11247. [PMID: 34681905 DOI: 10.3390/ijms222011247] [Reference Citation Analysis]
13 Buchfelder M, Schlaffer SM. Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas. Rev Endocr Metab Disord 2020;21:253-61. [PMID: 32500483 DOI: 10.1007/s11154-020-09563-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. Journal of the Endocrine Society 2022;6:bvab190. [DOI: 10.1210/jendso/bvab190] [Reference Citation Analysis]
15 Ng S, Messerer M, Engelhardt J, Bruneau M, Cornelius JF, Cavallo LM, Cossu G, Froelich S, Meling TR, Paraskevopoulos D, Schroeder HWS, Tatagiba M, Zazpe I, Berhouma M, Daniel RT, Laws ER, Knosp E, Buchfelder M, Dufour H, Gaillard S, Jacquesson T, Jouanneau E. Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien) 2021. [PMID: 34365544 DOI: 10.1007/s00701-021-04953-6] [Reference Citation Analysis]